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Abstract
Background: Tobacco-smoke is the major etiological factor related to lung cancer. However, other important factor
is chronic wood smoke exposure (WSE). Approximately 30 % of lung cancer patients in Mexico have a history of WSE,
and present different clinical, pathological and molecular characteristics compared to tobacco related lung cancer,
including differences in mutational profiles. There are several molecular alterations identified in WSE associated lung
cancer, however most studies have focused on the analysis of changes in several pathogenesis related proteins.
Methods: Our group evaluated gene expression profiles of primary lung adenocarcinoma, from patients with history
of WSE or tobacco exposure. Differential expression between these two groups were studied through gene expression
microarrays.
Results: Results of the gene expression profiling revealed 57 statistically significant genes (p < 0.01). The associated
biological functional pathways included: lipid metabolism, biochemistry of small molecules, molecular transport, cell
morphology, function and maintenance. A highlight of our analysis is that three of the main functional networks
represent 37 differentially expressed genes out of the 57 found. These hubs are related with ubiquitin C, GABA(A)
receptor-associated like protein; and the PI3K/AKT and MEK/ERK signaling pathways.
Conclusion: Our results reflect the intrinsic biology that sustains the development of adenocarcinoma related to WSE
and show that there is a different gene expression profile of WSE associated lung adenocarcinoma compared to tobacco
exposure, suggesting that they arise through different carcinogenic mechanisms, which may explain the clinical and
mutation profile divergences between both lung adenocarcinomas.
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Background
Lung cancer is the first cause of death from cancer [1]. Ap-
proximately 85 % of diagnosed patients present Non-Small
Cell Lung Cancer (NSCLC), and adenocarcinoma is the
most frequent histological type. Despite efforts, innovations,
and progress in diagnosis and treatment, 5-year overall
survival is approximately 15 % with high mortality rates [2].
Tobacco smoking is the main risk of lung cancer. Other
factors include pulmonary tuberculosis, genetic sus-
ceptibility, exposure to secondhand smoke, asbestos
and radon [3]. In Mexico, the crude mortality rate of
lung cancer is 6.68 per 105 individuals, representing nearly
9000 cases per year, most of them presenting metastatic
stage at diagnosis [4, 5].
Nowadays about 15 % of lung cancer in men and 53 % in
women is not associated to smoking [6]. Besides, due to
the impact of tobacco control policies, a bigger percentage
of non-smoking patients with lung cancer is expected in
the following years. According to cancer statistics from the
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USA, lung cancer death rates declined 36 %, from 1990 to
2011, among males and 11 %, between 2002 and 2011,
among females due to reduced tobacco use as a result of
increased awareness of the health hazards of smoking and
the implementation of comprehensive tobacco control [2].
There have been reports of a doubling in the annual inci-
dence of lung cancer in never smokers, identifying as well
that non-smoker NSCLC patients tend to be female and
young [7, 8]. Regarding mortality, never smokers present
lung cancer death rates greater in men than in women and
a large fraction of cases have no identified risk factors [9].
Meanwhile former smokers present an increased risk of
lung cancer but cumulative risk decreases with earlier
smoking cessation compared to smokers who continue
smoking [10].
Chronic wood smoke exposure (WSE) is related to ob-
structive pulmonary disease in developing, European and
American countries [11, 12]. Wood dust has also been
identified as a human carcinogen and a risk factor for lung
cancer [3, 13]. Wood byproducts such as benzene, 1-
butadiene, formaldehyde and acetaldehyde, are well-known
carcinogens [14]. For more than 50 years, WSE has been
associated with an increased risk of lung cancer as com-
pared with pulmonary tuberculosis, interstitial lung disease
and various pulmonary conditions (OR: 1.9; 95 % confi-
dence interval (CI): 1.1–3.5) after adjusting for age, educa-
tion, socioeconomic status and tobacco smoke exposure
[13]. In Mexico, approximately 16 % of the population has
long-term exposure to wood smoke for residential heating
and/or cooking, and 30 % of lung cancers are associated
with WSE [5, 15]. Molecular assays have shown up-
regulation and phosphorylation of p53 in WSE related lung
cancer [16]. Moreover, WSE is associated with macrophage
dysfunction and an increase in the activity of metallopro-
teinases, like MMP-2 and MMP-9, which could be related
to lung injury in chronic obstructive pulmonary disease
and have a role in the physiopathology of lung cancer [17].
Ethnical origins and different risk factors for lung cancer
might explain the distinct mutation profiles, as in the case
of epidermal growth factor receptor (EGFR) and KRAS for
Asians, Caucasians and Latins [18–20]. Our group previ-
ously reported a high rate of treatment response and a
better outcome in patients with WSE related lung cancer
treated with EGFR-Tyrosine Kinase Inhibitors (TKIs) [21].
We have further described that WSE related lung cancer
is associated with an older age at diagnosis, adenocarcin-
oma histology, pleural effusion, high prevalence of EGFR
mutations (55.4 %) and a low prevalence of KRAS muta-
tion (6 %), compared to patients with smoking history
[15]. These situations indicate clear differences in the mo-
lecular and clinical evolution of WSE related lung cancer
compared with tobacco associated lung cancer.
In order to further analyze the molecular differences
observed in WES-related lung cancer, the objective of
our work was to compare the genetic expression profile




This study used clinical, longitudinal, prospective, obser-
vational and analytical cohorts with the selection of a
non–probabilistic sample type. The protocol was approved
by the Scientific and Bioethical committees of the Instituto
Nacional de Cancerología (INCan, 008102510M1, CB451).
Patients and tissue samples
Patients admitted to the INCan with a pulmonary lesion
suggestive of primary lung cancer were prospectively biop-
sied from January 2008 to June 2011. After informed con-
sent, tissue was obtained by computer tomography-guided
tru-cut (Care fusion, San Diego, CA, USA) from the clinic-
ally suspected primary tumor. Data were excluded from the
analysis if there was no histological diagnosis, a different
type of primary cancer was present, or if the pathology re-
port indicated a histology different from lung adenocarcin-
oma. The patients with histologically confirmed advanced
lung adenocarcinoma (stages III B and IV) were eligible for
inclusion in the study (Fig. 1).
A complete medical history that included a detailed his-
tory of smoking, wood smoke exposure and a physical
examination was obtained. Tumor specimens were col-
lected at the time of diagnosis. WSE was defined as expos-
ure to fumes resulting from burning wood in fireplaces
and wood stoves for ≥ 4 h per day for ≥ 5 years. The WSE
exposure index was calculated as the average number of
hours spent on cooking daily per the total number of years
spent cooking [22]. A smoker was defined as being some-
one having a lifetime exposure of more than 100 cigarettes
[6]; the tobacco-smoking index was calculated by multiply-
ing the number of cigarette packs consumed per day by
the number of years spent smoking [15].
RNA isolation and RNA preparation for microarrays
Primary tumor core-biopsy was performed prior to any
treatment and snap-frozen in nitrogen for RNA extraction.
A trained pathologist confirmed histological diagnosis and
quantified tumor cell percentage.
The procedure for extraction and purification of total
RNA from tissue (up to 5 mg tissue) was done using
RNeasy Micro Kit (QIAGEN, Germany) (cat. 217084).
RNA integrity was evaluated by capillary electrophor-
esis using the Agilent Bioanalyzer 2100 (Agilent Tech-
nologies, Santa Clara, CA). Samples with RNA integrity
number (RIN) of six or higher were included for micro-
array analysis.
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RNA amplification and expression microarray analysis
Gene expression analysis was done using the Affymetrix
GeneChip® Human Gene 1.0 ST Array System, which eval-
uates the expression of 28,869 different genes. Sample pro-
cessing was done following the manufacturer’s instructions.
Strategy for microarray gene-expression analysis
Statistical analysis for differential expression was conducted
using R and Bioconductor. Background correction for non-
specific hybridization was performed with Robust Multiar-
ray Average (RMA) [23] which uses a fairly complex statis-
tical model that supposes both additive and multiplicative
noise components. After background correction to the
individual probes, quantile normalization [24] was applied,
both steps are implemented in the oligo package [25].
Normalized and corrected probes are summarized into
probe sets using the median polish algorithm, which is a
type of robust 2-way ANOVA, where one factor is the array
and the other is the probe set. The algorithm is robust to
outliers, making single probes with large values are down-
weighted. Batch correction was also applied to all samples
using combat in the sva package [26]. Differential expres-
sion was identified through linear models implemented in
the limma package [27], genes were selected as significant
according to two summary statistics: p-value (<10−2) and
fold- changes larger than 1.2 in absolute values.
For the biological networks and functional analysis, we
used QIAGEN’s Ingenuity Pathway Analysis (IPA®, QIA-
GEN Redwood City, http://www.ingenuity.com/). IPA was
used to identify gene-signaling pathways that were involved
in biological processes of WSE versus tobacco exposure.
Networks of these genes were algorithmically generated
based on their connectivity and assigned a score. The score
ranks networks according to how relevant they are to the
Fig. 1 Consort
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input genes not necessarily to the quality or significance of
the network. The network indicates the molecular relation-
ships between genes/gene products. Node color indicates
up- or down-regulation and intensity is associated to degree
of regulation. It is important to remark that uncolored
genes were not identified as differentially expressed in
our experiment, however, IPA integrate those into the
computationally generated networks based on the col-
lected evidence indicating a relevance to this network.
Identification of differentially expressed genes
Significant changes in gene expression were selected ac-
cording to p-values <10−2 and fold changes in absolute
values larger than 1.2. Differences in gene expression are
shown in volcano plots representing fold changes in log2
base along the x-axis and the level of trust in the form of –
log10(p-values) along the y-axis. A value of 2 on the y-axis
represents our cut-off of 10−2 (top right and left corners).
Heat maps show gene profiles clustered, result of an un-
supervised hierarchical clustering of genes significantly
different (p < 0.01) between patients with different risk
factors.
Results
Overall 53 tumor samples were collected, and 29 samples
were suitable for gene expression analysis. Two samples
with suitable material were excluded due to patients’ history
of asbestos exposure and thoracic radiotherapy. The 27
remaining samples included 12 patients with an exclusive
history of tobacco exposure and 15 patients with exclusive
WSE history (Fig. 1).
Clinical and molecular results
The clinical characteristics of the 27 patients included in
the microarray analysis are: mean age 62.9 ± 11.7 years,
55.6 % (15/27) were females, WSE was present on 55.6 %
of patients (15/27) and 44.4 % (12/27) had tobacco expos-
ure (Table 1). EGFR mutational status was statistically
significant (p = 0.003); 53 % (8/15) of patients presented
positive EGFR mutation status in the WSE group
(Table 2).
On differentially expressed genes in WSE compared with
tobacco smoke exposure
Figures 2 and 3 show differences in gene expression, the
gene profile shown in the clustered heat map displays
significantly different genes (p < 0.01) between patients
with WSE versus patients with a tobacco smoking history.
The comparison of adenocarcinomas from patients ex-
posed to tobacco smoke versus WSE revealed that both
groups can be separated based on the differential expres-
sion of 57 genes (p < 0.01), 35 up-regulated and 22 down-
regulated (Fig. 3).
Enrichment and functional analysis through biological
networks was conducted using IPA software. The top func-
tional networks were related to five different biological cat-
egories as follows: Lipid metabolism; Biochemistry of small
molecules; Transport of molecules; Cell morphology; Func-
tion and cell maintenance. Table 3 lists the up- and down-
regulated genes with significant changes in expression from
patients with NSCLC exposed to tobacco smoke versus
WSE (p < 0.01). The two main categories with greater
differences were transport of molecules and cell function
and maintenance.
Three functional networks are shown, these networks
involve the majority of the differentially expressed genes
(37/57) and have: Ubiquitin C (UBC, score 28, Fig. 4),
GABA(A) receptor-associated like protein (GABARAPL1,
score 28, Fig. 5) and PI3K/AKT and MEK/ERK genes
(score 26, Fig. 6) as main hubs of the network. Moreover,
when the networks were overlapped, all up and down
Table 1 Baseline clinical pathological and molecular











Median (IQR) 104 ± 10
Tobacco-smoking index













Abbreviations: NSCLC non–small-cell lung cancer, SD standard deviation, ECOG
PS eastern cooperative oncology group performance status, EGFR epidermal
growth factor receptor, WSE wood smoke exposure
*Kolmogorov-Smirnov test p value: 0.20
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regulated genes appear around the PI3K/AKT and MEK/
ERK signaling pathways (Fig. 7).
Discussion
Although the majority of lung cancer occurs in smokers,
25 % of worldwide lung cancer occurs in life long never
smokers [28], being the 7th largest cause of cancer-related
mortality in this group [29], presenting a wide-ranging
geographic incidence and risk factors such as asbestos, air
pollution, radon, arsenic compounds, cadmium, chromium,
ionizing radiation and WSE [30]. Additionally, molecular
profiles observed in lung cancer are critically different
among smokers and non-smokers particularly identified
in genes such EGFR, KRAS, P53 and ALK [31]. In the
case of WSE, there have been association with NSCLC
and adenocarcinoma histology, EGFR mutations, a reverse
association with KRAS mutations and higher response to
EGFR-TKIs [15] making it a distinctive disease entity in-
side the group of never smokers which would be a good
candidate for personalized diagnostic and therapeutic
approaches. Therefore, lung cancer associated to WSE
presents unique characteristics that make it a distinctive
entity of disease within the group of never smokers; thus,
it could be a good candidate for personalized diagnostic
and therapeutic approaches.
There is evidence of differential expression profiles asso-
ciated with the bronchial epithelium of tobacco-smokers
that sustains carcinogenesis [32], as well as the determin-
ation of tobacco-smoke transcriptional changes in onco-
genes and anti-oncogenes [33]. Our study shows that the
gene expression profiling of samples from patients with
WSE is different from patients using tobacco.
Our group has previously reported that lung cancer re-
lated to tobacco smoke and WSE exhibits different clinical
and pathological characteristics that may be related to dif-
ferent mechanisms, and this is reflected in their response
rate and overall survival in NSCLC patients [15]. However,
in the present report we show a specific gene expression
profile for WSE that involves 57 genes. Using biological or
functional network analysis, 37 genes were identified
around UBC, GABARAPL1 genes and PI3K/AKT and
MEK/ERK signaling pathways.
The UBC hub in Network 1 (Fig. 4) is involved in cellu-
lar homeostasis and signaling. It was originally activated
to degrade misfolded or disused proteins, but it has been
recently associated with the cell cycle, DNA repair, endo-
cytosis, antigen processing and apoptosis [34]. Recently,
Table 2 Clinical and molecular characteristics related to







Female 12 5 0.49
Male 3 7
AgeMean (±SD) 63(11.88) 62.9(12.12) 0.89
aEGFR mutation (N= 9)
Positive 8 1




Recurrent 2 2 0.70
*Non-parametric test: Mann-Whitney U test
a9/27 patients had EGFR mutation
Fig. 2 Volcano Plot showing gene differential expression of patients with adenocarcinoma and history of wood smoke exposure vs. tobacco
smoke exposure. Fold changes are represented in log2 base along the x-axis and the level of trust in the form of –log10 (p < 0.001) along the
y-axis. The cut off value of 10−2 used is 2 on the y-axis (top right and left corners). Red and green dots represent up and down-regulated genes
respectively: Fold change (≥1.2) and significance level (p < 0.001). Other colors: yellow indicates significant but low fold change, magenta shows
not statistically robust changes and blue shows low fold change with low statistical significance
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Fig. 3 Heat map result of an unsupervised hierarchical clustering of genes significantly different (p < 0.01) of NSCLC adenocarcinoma exposed to
wood smoke versus tobacco smoke. Each column represents a patient and each row a gene. The heat map indicates the level of gene expression.
Red: high expression; Green: Low expression
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Tang et al. demonstrated that the inhibition of the ubiqui-
tin system decreased the proliferation and radio-resistance
in the H1299 cell line (NSCLC cells) [35]. In this regard, a
clinically relevant observation is the approval of
bortezomib as an inhibitor of the protein degradation sys-
tem in human cancer [32].
The GABARAPL1 hub in Network 2 (Fig. 5) is a highly
conserved protein throughout evolution. It is related to
Table 3 List of genes with changed expression that are significantly (p< 0.01) over- and under-regulated in patients with NSCLC exposed
to wood smoke versus tobacco (five IPA biological functions categories)
Symbol Log ratio p-value Lipid metabolism Small mol. bioch. Mol. transport Cell morphology Cell. func. and main.
Upregulated genes
HIST1H3I 0.763 9.86E-03 ✓ ✓ ✓
DONSON 0.554 3.82E-03 ✓ ✓ ✓
ENTPD6 0.472 2.98E-03 ✓ ✓ ✓
RIBC2 0.383 8.19E-04 ✓ ✓ ✓
VASN 0.286 9.15E-03 ✓ ✓ ✓
ASL 0.251 3.38E-03 ✓ ✓ ✓
DMC1 0.165 6.49E-03 ✓ ✓ ✓
ATP4B 0.12 4.14E-03 ✓ ✓ ✓
MEST 0.601 8.79E-03 ✓ ✓
TMEM184A 0.34 6.13E-03 ✓ ✓
ATG9A 0.262 6.82E-03 ✓ ✓
PYCR1 0.499 8.28E-03 ✓ ✓
RBM38 0.301 8.38E-03 ✓ ✓
HNRNPD 0.219 8.57E-03 ✓ ✓
ZNF239 2.60E-01 9.77E-04 ✓ ✓
Downregulated genes
SPTLC2 −0.412 6.28E-03 ✓ ✓ ✓
TBRG1 −0.374 3.42E-03 ✓ ✓ ✓
ZNF175 −0.358 8.97E-03 ✓ ✓ ✓
ZNF594 −0.351 7.40E-03 ✓ ✓ ✓
TEX12 −0.125 7.24E-03 ✓ ✓ ✓
SLC16A10 −0.777 9.14E-03 ✓ ✓
GABARAPL1 −0.61 9.62E-04 ✓ ✓
PAPPA −0.516 3.63E-04 ✓ ✓
MED31 −0.261 8.96E-03 ✓ ✓
NDUFAF1 −0.254 6.22E-03 ✓ ✓
CCDC144NL −0.224 9.26E-03 ✓ ✓
CNTN4 −0.189 9.02E-03 ✓ ✓
NXPE2 −0.145 9.07E-03 ✓ ✓
RCOR3 −0.143 8.15E-03 ✓ ✓
SGK1 −0.718 6.48E-03 ✓ ✓
PTPRG −0.686 2.63E-03 ✓ ✓
DIO2 −0.623 8.90E-03 ✓ ✓
RBL2 −0.369 6.19E-03 ✓ ✓
ARNTL −0.366 9.77E-03 ✓ ✓
TRAF6 −0.329 6.87E-03 ✓ ✓
MBP −0.246 4.43E-03 ✓ ✓
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autophagy and vesicle intracellular transport [36]. Its
participation in cancer is still not clear, but it has been
reported that lower levels of this transcript correlates with
decreased survival in patients with neuroblastoma [37]
and increased metastasis in breast cancer [36]. On the
other hand, the ectopic over-expression of GABARAPL1
inhibits cancer cell proliferation and tumor growth in
mice [38]. There are other reports that relate low expres-
sion of this gene in several cancer cell lines [39].
Regarding the last network, there have been reports that
show that PI3K/AKT and MEK/ERK signaling pathways
are altered in NSCLC and their activation is associated
with malignant transformation and drug resistance (Figs. 6
and 7). MEK and PI3K inhibitors can inhibit cell
Fig. 4 Network 1 (Score: 28/Ratio: 0.353/p value: 1.48E-24). Genes (p < 0.01) in wood smoke exposure in NSCLC around the UBC gene. Red mark:
up-regulated genes. Green mark: down-regulated genes. The node shapes denote enzymes ( ), phosphatases ( ), kinases ( ), peptidases ( ),
G-protein coupled receptor ( ), transmembrane receptor ( ), cytokines ( ), growth factor ( ), ion channel ( ), transporter ( ), translation factor
( ), nuclear receptor ( ), transcription factor ( ) and other ( )
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proliferation in NSCLC; however, for apoptosis activation,
both signaling pathways must be simultaneously inhibited
[40, 41], a situation that is directly related to the fre-
quently observed EGFR-TKI resistance in this tumor.
There are other reports showing that EGFR mutations
function as inductors to sensitization to TKIs through
PI3K/AKT and MEK/ERK signaling pathways [41–45]. It
has also been demonstrated that cases with EGFR
mutations have a major sensibility to the EGFR-TKIs,
using inhibitors from PI3K/AKT and MEK/ERK [41–45].
On a clinical note, our group has previously reported
the association between NSCLC adenocarcinoma and
positive EGFR mutation status in patients with history
of WSE compared to tobacco smoke exposure.
WSE is also related to gene promoter methylation that
synergistically increases the risk for reduced lung function
Fig. 5 Network 2 (Score: 28/Ratio: 0.375/p value: 6.11E-25). Genes (p < 0.01) in wood smoke exposure in NSCLC around the GABARAPL1 gene. Red
mark: up-regulated genes. Green mark: down-regulated genes. The node shapes denote enzymes ( ), phosphatases ( ), kinases ( ), peptidases
( ), G-protein coupled receptor ( ), transmembrane receptor ( ), cytokines ( ), growth factor ( ), ion channel ( ), transporter ( ), translation
factor ( ), nuclear receptor ( ), transcription factor ( ) and other ( )
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in cigarette smokers [46]. A recent report describing the
toxicological characteristics associated with WSE in A549
cell lines, including high levels of polycyclic aromatic hy-
drocarbons (PAH) and low level of water-soluble metals,
showed an enhanced level of free radicals, DNA damage
and the major expression of inflammatory/oxidative stress
genes [47]. There is evidence that some potential molecu-
lar targets, such as EGFR and the ErbB family receptor,
are usually altered in epithelial tumors [48]. EGFR medi-
ates cell proliferation, differentiation, survival, angiogen-
esis and migration, and is overexpressed in approximately
40–80 % on NSCLC tumors [49–51].
Clinically, it is known that EGFR inhibitors in NSCLC
extend survival after first-line or second-line therapy in
patients with EGFR mutations [52]. These mutations are
more frequent in specific populations, including women,
Asian and Hispanic ethnicities, never-smokers and adeno-
carcinoma histology [18, 53, 54]. Activating mutations in
EGFR leads to constitutive tyrosine kinase activation and
oncogenic transformation of lung epithelial cells [12, 13].
In this sense, the presence of these common activating
EGFR mutations is tightly associated with sensitivity to
reversible EGFR- specific tyrosine kinase inhibitors (e.g.:
erlotinib or gefitinib). Patients with these mutations
Fig. 6 Network 3 (Score: 26/Ratio: 0.134/p value: 2.09E-17). Genes (p < 0.01) in wood smoke exposure in NSCLC around the PI3K/AKT and MEK/
ERK signaling pathways. Red mark: up-regulated genes. Green mark: down-regulated genes. The node shapes denote enzymes ( ), phosphatases
( ), kinases ( ), peptidases ( ), G-protein coupled receptor ( ), transmembrane receptor ( ), cytokines ( ), growth factor ( ), ion channel
( ), transporter ( ), translation factor ( ), nuclear receptor ( ), transcription factor ( ) and other ( )
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display EGFR-TKIs response rates of approximately 70 %
a median progression free survival (PFS) of approximately
9–12 months and overall survival rates that may exceed
20–32 months [55]. Most patients will experience disease
progression and drug resistance attributed to the develop-
ment of other second mutations or with the presence of
other uncommon EGFR mutations [56]. Certain thera-
peutic relations in NSCLC include the main oncogenic pro-
tein KRAS-GTP with biological significance between EGFR
and PI3K/AKT or MEK/ERK pathways [56]. The presence
of KRAS mutations leads to an increased signal through
the MEK/MAPK transduction pathway [56]. Rare cases of
mutations of MEK have been reported in NSCLC [57].
Preclinical studies in both the KPC mouse model as well as
patient-derived xenografts have shown that blocking the
MAPK pathway at MEK results in a decrease of cell prolif-
eration and a subsequent halt in tumor growth [58]. The
activation of EGFR recruits PI3K to the cell membrane and
Fig. 7 Overlapping networks and related genes (p < 0.01) in wood smoke exposure in NSCLC. Red mark: up-regulated genes. Green mark:
down-regulated genes. Purple lines reflect the sites of intersections between our study genes (p < 0.01) and the main canonical networks
(PI3K/AKT and MEK/ERK) associated with NSCLC. The node shapes denote enzymes (♦), phosphatases ( ), kinases ( ), peptidases ( ),
G-protein coupled receptor ( ), transmembrane receptor ( ), cytokines ( ), growth factor ( ), ion channel ( ), transporter ( ), translation factor
( ), nuclear receptor ( ), transcription factor ( ) and other ( )
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phosphorylates phosphatidylinositol-2-phosphate (PIP2) to
phosphatidylinositol-3-phosphate (PIP3), which in turn
activates AKTand several downstream effectors [59]. Inhib-
itors of both PI3K and AKT have been developed [60],
although inhibition of PI3K is complicated by the fact that
there are multiple isoforms of the protein [61]. Another
biological interaction takes place on KRAS is one that
directly activates PI3KCA [62]. Unlike most oncogenic
driver mutations on NSCLC, PI3K mutations may occur in
association with EGFR or KRAS mutations [63]. Although
rare, PI3K/AKT/mTOR pathway activation may occur
through AKT mutations in NSCLC [64]. Clinical evidence
has shown that reversible EGFR-TKIs are considered the
frontline treatment for advanced NSCLC patients harbor-
ing EGFR mutations [65]. New emerging evidence suggests
that the anti-tumor activity of EGFR-TKIs in resistant
NSCLC cell lines can be enhanced by combined therapy
with other regimens. Early efforts have shown that cetuxi-
mab, produced synergistic anti-proliferative effects when
used in combination with gefitinib or erlotinib [66]. Our
analyses provide biological networks relationships between
37 genes and PI3K/Akt and MEK signaling for understand-
ing the biologic properties of WSE effects as a carcinogenic
factor in NSCLC. It also shows useful common pathway
maps for a future understanding of the disease and the
development of new therapeutic targets.
Whilst the differences in gene expression patterns
between WSE or tobacco-related lung cancer that we
identified in this paper provide an important insight
into the molecular basis of the clinical and biological
differences between these two tumors, there is a limita-
tion regarding the small sample size. However, this is
countervailed by a thorough characterization of the sam-
ples, a detailed clinical history and close follow-up on all
patients. It is imperative to continue further study to valid-
ate the potential biological and clinical implications of our
findings.
Conclusion
In conclusion, our results suggest a differential gene expres-
sion profile for WSE or tobacco-related lung cancer, which
suggests different carcinogenesis mechanisms between both
risk factors and enlightens the clinical-pathological
and mutational profiles between both groups with
adenocarcinoma.
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